Kornimate/medical-research-clean huggingface dataset:
epiction of the genomic and genetic landscape identifies ccl5 as a protective factor in colorectal neuroendocrine carcinoma

Conditions: Colorectal Neuroendocrine Carcinomas (CRNEC); Genomic Landscape; Genetic Landscape; Prognosis; CCL5; PAX5

Summary: background: colorectal neuroendocrine carcinomas (crnecs) are highly aggressive tumours with poor prognosis and low incidence. to date, the genomic landscape and molecular pathway alterations have not been elucidated. methods: tissue sections and clinical information were collected as an in-house cohort (2010-2020). large-scale genomic and genetic panels were applied to identify the genomic and genetic alterations of crnec. through the depiction of the genomic landscape and transcriptome profile, we compared the difference between crnec and cr neuroendocrine tumours (crnets). immunohistochemistry (ihc) staining and immunofluorescence (if) staining were performed to confirm the genetic alterations.


Eligibility criteria:
inclusion criteria: - tissues from colorectal neuroendocrine carcinomas exclusion criteria: - no
marijuana for hiv-related peripheral neuropathy

Conditions: Peripheral Nervous System Diseases; HIV Infections

Summary: to evaluate whether smoked marijuana reduces pain in people with hiv-related peripheral neuropathy.

the study will include subjects with peripheral neuropathy caused either by hiv-disease or antiretroviral medication for the treatment of hiv. a neurologist will conduct a neurological and pain evaluation to determine eligibility for the study. subjects who meet all eligibility criteria will be admitted to the general clinical research center at san francisco general hospital for seven days. subjects will be randomized (like a toss of a coin) to smoke marijuana or a placebo (cigarettes with no thc).

Eligibility criteria:
inclusion criteria: * hiv positive. * be 18 years or older. * diagnosis of hiv-related painful neuropathy. * stable antiretroviral therapy or no antiretroviral therapy for at least 8 weeks. * prior use of marijuana, at least 6 occasions in their lifetime prior to enrollment. exclusion criteria: (not allowed) * current use of smoked tobacco products. * current methadone treatment. * use of smoked marijuana within 30 days of enrollment. * diagnosis of diabetes mellitus. * currently receiving treatment with corticosteroids. * use of inh, dapsone or metronidazole within 8 weeks prior to enrollment. * severe heart disease, uncontrolled high blood pressure or lung disease. * women who are pregnant or breastfeeding.

Keywords: treatment experienced complementary therapies neuropathy peripheral neuropathy hiv-related peripheral neuropathy hiv
implementing the wuqinxi on patients with pulmonary arterial hypertension

Conditions: Pulmonary Arterial Hypertension PAH

Summary: aims and objective: the primary objective of this study was to assess the effects of a traditional chinese qigong practice known as wuqinxi on activity tolerance，negative emotions and quality of life in pulmonary arterial hypertension patients. methods: in the current prospective, randomized-controlled clinical trial, 60 patients with pulmonary arterial hypertension were randomly assigned to one of two groups: intervention or control. participants in the intervention group received targeted pharmacological therapy and five sessions of qigong exercise per week. in contrast, individuals in the control group underwent targeted drug therapy and routine care. observe the change in exercise tolerance as measured by the 6-minute walking distance (6mwd). serological indicators (n-terminal brain natriuretic peptide precursor, nt-pro bnp) ,negative emotions(phq-9/gad-7)and the mos item short form health survey (sf-36) or emphasis-10 were used to assess patients condition and quality of life.

in the previous study, we examined the effects of comprehensive respiratory function exercise on exercise tolerance in patients with pah. the results indicated that limb exercise combined with breath regulating guidance affects patients' physical health.given these tcm principles, the current study investigated the clinical utility of wuqinxi for improving patients' exercise tolerance and quality of life by comparing the intervention and control groups' nt-pro bnp scores, 6mwd data, negative emotionsand quality of life indices.

Eligibility criteria:
inclusion criteria: * (1) patients with pah related to ipah(idiopathic pulmonary arterial), ctd(connective tissue disease), dpah(drug-induced pulmonary hypertension), chd(congenital heart disease) and associated with secondary disease, aged 18-75 years; (2)patients with pah as defined by the american college of cardiology foundation/american heart association (right heart catheterization: mpap≥20mmhg and pawp≤15mmhg); (3) patients with who pulmonary arterial hypertension functional class ii-iii; (4) patients on drug-based treatment for ≥1 month and in the recovery period; (5) could read, write, and comprehend chinese; (6) volunteered for this trial and provided written informed consent. exclusion criteria: * (1) patients unable or unwilling to complete the 6mwd; (2) the physician confirms that the disease requires bed rest or with severely impaired cardiopulmonary function, tumors, and limb dysfunction; (3) patients who were unable to complete the questionnaire independently; (4) a history of mental problems and cognitive impairment; or have had psychotherapy or taken any psychiatric medication in the past or present.(5) patients who were hospitalized with severe disease.
different does of acupuncture on premenstrual syndrome efficacy analysis

Conditions: Premenstrual Syndrome

Summary: the design of the study includes 3 groups for women with premenstrual syndrome, 1low dose acupuncture in the low-dose group, 2 high dose acupuncture in the high-dose group, and 3 the drug group (contraceptives) . serum marker change of pge2, ca125, e2, and progesterone in enrolled patients will be measured before and after treatment, along with vas and mdq questionnaires. the treatment efficacy of different groups and the relationship between pms and patients tcm syndrome pattern will also be recorded and estimated.

premenstrual syndrome (pms) is the sum of a group of symptoms (including physical and psychological symptoms) that occurs during the luteal phase of the menstrual cycle. women who have such symptoms have been estimated as high as 75%; of which 3% to 8% are severe symptoms, called premenstrual dysphoric disorder (premenstrualdysphoric syndrome, pmdd). the two groups are very similar. pms is mostly for physical discomfort, while pmdd is for emotional problems, affecting women's sleep seriously. regarding the treatment of premenstrual syndrome (pms), western medicine adopt oral contraceptive pills (ocp) as the first-line medication. however, the common side effects of ocp, such as headache, dizziness, nausea, vomiting, depression, breast pain and so on are also troublesome, in recent years, some women also use acupuncture as an adjunctive replacement therapy because of its safety and fewer side effects. nevertheless, the factors affecting treatment effect of acupuncture and moxibustion. such as the selection of acupoint s ( of which meridians) or number(dose) of acupuncture ,etc., maight affect the efficacy, yet the relevant research on this issue is not enough. in traditional chinese medicine theory, acupuncture and moxibustion regulate the energy of the meridians and adjust blood and qi, which in turn help the balance of yin and yang. female menstrual cycle is a process of conversion between yin and yang in tcm theory. while in western medicine, it is regulated by the endocrine system.

Eligibility criteria:
inclusion criteria: 1.15 to 49 years 2.with a history of regular menstrual cycles (28days±7 days) 3.symptoms：breast pain、dizziness、bloating、cramps、nausea、vomiting、 diarrhea、headache、 fatigue，etc exclusion criteria: 1. irregular menstrual cycles 2. intrauterine contraceptive device (iucd/iud) 3. uncontrolled neurological diseases 4. lactation， pregnant women，or those with plans to get pregnant in the coming half year

Keywords: acupuncture premenstrual syndrome tcm syndrome
effect of transcranial direct current stimulation on the voice

Conditions: Voice and Resonance Disorders; Transcranial Direct Current Stimulation; Voice Disturbance

Summary: the goal of this clinical trial is to verify the effect on the voice of transcranial direct current stimulation (tdcs) in vocally healthy non-singers. the main question it aims to answer is: what is the brain area in which tdcs promotes better vocal performance in vocally healthy individuals? each participants received anodal tdcs applied at an intensity of 2 ma for a duration of 20 minutes for tdcs stimulations in different areas with a 7-day washout period between stimulations. vocal assessments was conducted before and after the intervention. the targeted places were the primary motor cortex (m1), primary somatosensory cortex (s1), cerebellum, and dorsolateral prefrontal cortex (dlpfc).

recently, non-invasive brain stimulation (nibs) techniques , including transcranial direct current stimulation (tdcs), have been employed to enhance vocal skills. tdcs can be used to temporarily and reversibly modulate brain functions and is an increasingly popular tool for investigating the relationships between the brain and behavior . the aim of the present study is investigate the effect of tdcs applied to different areas on the voice of vocally healthy non-singers. this is a randomized crossover clinical trial, approved by the research ethics committee of the federal university of pernambuco, number 5,758,856. vocally healthy people from the city of recife and its metropolitan region, aged between 18 and 45 years, participated in the study.each participant underwent four tdcs stimulations in different areas with a 7-day washout period between stimulations to study their vocal assessments before and after tdcs. the targeted places were the primary motor cortex (m1), primary somatosensory cortex (s1), cerebellum, and dorsolateral prefrontal cortex (dlpfc). all participants were subjected to voice acessments analysis immediately before and after tdcs application in each area. data normality will be analyzed using the shapiro-wilk test, rejecting the hypothesis of normal distribution when p\<0.05. anova will be applied to design repeated measures in case of normality and in the existence of asymmetric data, friedmann's anova will be used for repeated measures. for the comparison of values before and after application of the technique and between modes of execution of the technique (with and without non-invasive neuromodulation), tests will be applied for related and independent samples, respectively, with a significance level of 5%

Eligibility criteria:
inclusion criteria: * non-singers with healthy voice exclusion criteria: * smokers * those who present signs and symptoms of laryngeal, pharyngeal or respiratory diseases at the time of collection * volunteers who make regular use of neuroactive drugs * those who have metallic implants or a pacemaker * people that have any history of seizures or epilepsy

Keywords: transcranial direct current stimulation voice speech therapy
switch from combivir or trizivir to truvada - mitochondrial effects

Conditions: HIV

Summary: study subjects receiving the antiretroviral drugs combivir or trizivir, will be randomized to switch to truvada-containing highly active antiretroviral therapy (haart) or to continue on combivir or on trizivir. measurements will be performed at baseline and after 6 months after randomization to either continuing on trizivir or combivir, or to switching to truvada. measurements include maximal or peak oxygen consumption, lactate production and clearance, subcutaneous adipose tissue and limb fat contents, insulin resistance, liver and muscle fat contents, and plasma free fatty acid concentrations. the hypothesis underlying this study is that chronic therapy with thymidine analogue nucleoside reverse transcriptase inhibitors (nrtis), including zidovudine (azt), leads to clinically detectable mitochondrial dysfunction in several organ systems.

none different from the summary description above.

Eligibility criteria:
inclusion criteria: * infection with human immunodeficiency virus (hiv) with undetectable viral load * on combivir or trizivir * able to exercise and sign consent exclusion criteria: * other active illness * contraindication to magnetic resonance imaging (mri) scanning or maximal exercise.

Keywords: treatment experienced
body weight effects on glucophage's efficacy in chinese diagnosed t2dm patients

Conditions: Type 2 Diabetes Mellitus

Summary: the purpose of this study is to investigate the effect of the baseline body mass index (bmi) on the response to glucophage xr monotherapy in glycemic control in chinese patients with newly diagnosed type 2 diabetes


Eligibility criteria:
inclusion criteria: * signed written informed consent * age≥ 17 and \<80 years, * newly diagnosed t2dm (defined as t2dm diagnosed within 6 months prior to enrollment) * oral antidiabetic agents naïve (defined as without receiving any anti-diabetic medication therapy before, or having received anti-diabetic medication ≤ 14 days but not received any antidiabetic medication within the last 1 month prior to enrollment) * hba1c ≥ 7.0% and ≤10.0% exclusion criteria: * women of child bearing potential * body mass index (bmi)≥35 kg/m2 or bmi \<18.5 kg/m2 * hemoglobin a1c (hba1c)\>10.0% or \<7.0% * active liver disease and/or significant abnormal liver function * acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma * congestive heart failure defined as new york heart association (nyha) class iii or iv and /or left ventricular ejection fraction ≤40% * significant cardiovascular history with the past 6 months * severe retinopathy, persistent uncontrolled hypertension (sbp≥180mmhg, or dbp≥105mmhg) * severe chronic gastrointestinal disease * history of alcohol abuse or illegal drug abuse within the past 12 months * diagnosed anemia * creatine kinase ≥3 x uln * serum creatinine ≥1.5 mg/dl(133μmol/l) \[males\], ≥1.4 mg/dl(124 μmol/l)\[females\] * alanine amino transferase (alt) and/or aspartate amino transferase (ast)\> 1.5 x uln and/or total bilirubin \> 2 x uln * hemoglobin \<12g/dl \[males\], \<11g/dl \[females\] * allergies and adverse drug reactions * prohibited treatments and/or therapies * prisoners or subjects who are involuntarily incarcerated * subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness * subjects decline to participate
safety and efficacy of solithromycin in adolescents and children with community-acquired bacterial pneumonia

Conditions: Community-acquired Bacterial Pneumonia

Summary: this is a phase 2/3, randomized, open-label, active control, multi-center study to assess the safety and efficacy of solithromycin in children and adolescents with community-acquired bacterial pneumonia (cabp).

subjects who meet all inclusion/exclusion criteria and sign the informed consent/assent were enrolled. subjects were randomized to receive solithromycin or a comparator antibiotic, administered iv and/or by mouth (po) based on weight and age. subjects were treated daily for 5 to 7 days with oral solithromycin and 5 to 7 days with iv or iv-to-oral solithromycin. subjects were treated for 5 to 10 days with comparator antibiotics. subjects received safety and efficacy assessments during and after treatment.

Eligibility criteria:
inclusion criteria: * history of and/or documented fever (rectal, ear, or oral temperature ≥38°c or axillary temperature ≥37.5°c) or hypothermia (rectal, ear, or oral temperature \<35°c or axillary temperature \<34.5°c) * chest radiograph infiltrates consistent with bacterial pneumonia (or pneumonia caused by atypical bacterial agents); if a subject is outpatient and starting on oral therapy, a radiograph is not required. * presence of at least 2 of the following signs or symptoms: * cough * difficulty breathing * production of purulent sputum * chest pain * grunting * hypotension * tachycardia, defined as follows: 2 months to \<24 months: ≥160 beats/min 24 months to \<10 years: ≥140 beats/min * 10 years: ≥100 beats/min * tachypnea, defined as follows: 2 months to \<12 months: ≥50 breaths/min 12 months to \<5 years: ≥40 breaths/min * 5 years: ≥20 breaths/min * physical exam consistent with pulmonary consolidation * presence of at least 1 of the following: * leukocytosis (≥12,000 white blood cells \[wbc\]/mm3) * leukopenia (\<5000 wbc/mm3) * ≥10% immature neutrophils (bands) regardless of total peripheral wbc * elevated inflammatory markers (c-reactive protein or procalcitonin) * oxygen saturation \<97% on room air * organism consistent with a typical respiratory pathogen identified exclusion criteria: * ventilator-associated or hospital-acquired pneumonia * \>48 hours of systemic antibacterial therapy * confirmed or suspected bacterial meningitis * breast-feeding females * positive pregnancy test

Keywords: pneumonia macrolide pediatric
genetic inclusion by virtual evaluation

Conditions: Birth Defects; Multiple Congenital Anomaly; Neurodevelopmental Disorders

Summary: this study aims to transform the current clinical practice paradigm by leveraging an internally designed web-based model of delivery of care called consultagene to provide remote evaluation and genomic sequencing for improving genetic health of less resourced children with rare disorders living along the texas-mexico border.

inadequate access to genetics evaluation and genomic testing in the hispanic minorities living along the texas-mexico has marginalized the most vulnerable pediatric group. in this study, we will (1) implement a virtual web-based service, called consultagene for simplifying patient pathways and deliver virtual genetics evaluation in rio grande valley (rgv) (2) provide rapid genetic diagnoses through whole genome sequencing and interpretation of diagnostic studies for medical decision-making and improving health outcomes for the minorities, and (3) build genomic competency of front-line healthcare providers through education and machine learning to expedite referral of pediatric patients with suspected rare diseases for shortening diagnostic odyssey.

Eligibility criteria:
inclusion criteria: pediatric patients with undiagnosed rare genetic diseases residing in the rio grande valley and el paso in texas exclusion criteria: children with known genetic diseases
radiomics assess of bevacizumab plus chemo in colorectal cancer liver metastases

Conditions: Colon Cancer; Rectal Cancer; Liver Metastases

Summary: colorectal carcinoma with liver metastasis is one of the major problems bothering physicians worldwide. bevacizumab combined with chemotherapy is the standard treatment recommended by several guidelines. despite the high cost, a certain portion of patients couldn't benefit from this therapy. this study is aiming to find out the specific type of patients who would respond to bevacizumab by radiomics approach, and evaluate the prediction value of this imaging model with clinical and genetic factors.


Eligibility criteria:
inclusion criteria: 1. colorectal carcinoma confirmed by pathological result. 2. liver metastasis confirmed by imaging studies. 3. treatment of bevacizumab combined with chemotherapy chosen by mdt team. 4. ecog: 0-2. 5. normal laboratory studies including liver\\renal\\bone marrow functions. 6. expected lifespan more than 3 months. exclusion criteria: 1. previous treatment of colorectal cancer with liver metastasis. 2. diagnosed with other malignancies. 3. couldn't finish the trial due to several reasons such as allergy to chemotherapy drugs\\pregnancy or lactation\\chronic heart disease\\unable to sustain further treatment.

Keywords: colorectal cancer liver metastasis bevacizumab
medically intensive nutrition therapy program for obesity and diabetes in a low-income population

Conditions: Overweight; PreDiabetes; Diabetes Type 2; Obesity

Summary: this study is being done to better understand whether meal replacements can be an effective tool for weight loss and treatment of elevated blood sugars in people with obesity/overweight and diabetes/pre-diabetes who have a low income.

the medically intensive nutritional therapy (mint) program at massachusetts general hospital (mgh) weight center is a low-calorie nutrition plan that may offer a solution for those who have difficulty implementing a low-calorie dietary plan on their own. this study examines the effects of mint on weight loss and blood sugar control specifically in a low-income population and explores potential reasons for discontinuing the program.

Eligibility criteria:
inclusion criteria: * age 18-65 * body mass index (bmi) greater than or equal to 27 kg/m\^2 * hga1c greater than or equal to 5.7 percent or fasting glucose greater than or equal to 100mg/dl within the previous 6 months * low-income as defined by having a family income at or below 400 percent of the federal poverty level guidelines for 2022 exclusion criteria: * current use of antihyperglycemic agents (other than metformin) or approved anti- obesity medications or plans to start such regimens over the 3 months post-study enrollment * hba1c greater than or equal to 10 percent * plans to pursue bariatric surgery over the 6 months post-study enrollment * weight loss of greater than 5 kg within the previous 3 months * current active eating disorder, with the exception of binge eating disorder * severe active psychiatric disease or significant cognitive impairment deemed by investigator likely to impede adherence to piloted intervention * active illicit substance abuse * pregnant, breastfeeding, or considering pregnancy within the next 6 months * current participation in another clinical research trial deemed by investigator to conflict with current study